Gene-expression profiling in lung cancer: Still early days

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In summary, the infancy status in gene-expresion profiling in lung cancer is the result of multiple factors. A concert of efforts is needed to move the field forward. As a high-throughput tool at the molecular level, gene-expression profiling has a clear edge over traditional histological tumor assessment. However, the day of its clinical applications has yet to come. With consideration of the histological complexity of lung cancer, molecular classification for tumor subtypes needs to focus on cases that challenge routine pathological examination or classify tumors based on genes in pathways relevant to clinical outcomes. Tumor substaging alone has little clinical value if no impact is associated with treatment options and outcomes. A gene signature or panel that does not provide improved prediction independent from well-known predictors will lies likely be adopted clinically.

Original languageEnglish (US)
Pages (from-to)129-132
Number of pages4
JournalPharmacogenomics
Volume8
Issue number2
DOIs
StatePublished - Feb 2007

Fingerprint

Gene Expression Profiling
Lung Neoplasms
Neoplasms
Genes

ASJC Scopus subject areas

  • Pharmacology
  • Genetics(clinical)

Cite this

Gene-expression profiling in lung cancer : Still early days. / Yang, Ping; Sun, Zhifu D.

In: Pharmacogenomics, Vol. 8, No. 2, 02.2007, p. 129-132.

Research output: Contribution to journalArticle

@article{22924a17f78c4dc2bdb6781d4df62f6b,
title = "Gene-expression profiling in lung cancer: Still early days",
abstract = "In summary, the infancy status in gene-expresion profiling in lung cancer is the result of multiple factors. A concert of efforts is needed to move the field forward. As a high-throughput tool at the molecular level, gene-expression profiling has a clear edge over traditional histological tumor assessment. However, the day of its clinical applications has yet to come. With consideration of the histological complexity of lung cancer, molecular classification for tumor subtypes needs to focus on cases that challenge routine pathological examination or classify tumors based on genes in pathways relevant to clinical outcomes. Tumor substaging alone has little clinical value if no impact is associated with treatment options and outcomes. A gene signature or panel that does not provide improved prediction independent from well-known predictors will lies likely be adopted clinically.",
author = "Ping Yang and Sun, {Zhifu D}",
year = "2007",
month = "2",
doi = "10.2217/14622416.8.2.129",
language = "English (US)",
volume = "8",
pages = "129--132",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Gene-expression profiling in lung cancer

T2 - Still early days

AU - Yang, Ping

AU - Sun, Zhifu D

PY - 2007/2

Y1 - 2007/2

N2 - In summary, the infancy status in gene-expresion profiling in lung cancer is the result of multiple factors. A concert of efforts is needed to move the field forward. As a high-throughput tool at the molecular level, gene-expression profiling has a clear edge over traditional histological tumor assessment. However, the day of its clinical applications has yet to come. With consideration of the histological complexity of lung cancer, molecular classification for tumor subtypes needs to focus on cases that challenge routine pathological examination or classify tumors based on genes in pathways relevant to clinical outcomes. Tumor substaging alone has little clinical value if no impact is associated with treatment options and outcomes. A gene signature or panel that does not provide improved prediction independent from well-known predictors will lies likely be adopted clinically.

AB - In summary, the infancy status in gene-expresion profiling in lung cancer is the result of multiple factors. A concert of efforts is needed to move the field forward. As a high-throughput tool at the molecular level, gene-expression profiling has a clear edge over traditional histological tumor assessment. However, the day of its clinical applications has yet to come. With consideration of the histological complexity of lung cancer, molecular classification for tumor subtypes needs to focus on cases that challenge routine pathological examination or classify tumors based on genes in pathways relevant to clinical outcomes. Tumor substaging alone has little clinical value if no impact is associated with treatment options and outcomes. A gene signature or panel that does not provide improved prediction independent from well-known predictors will lies likely be adopted clinically.

UR - http://www.scopus.com/inward/record.url?scp=33847014530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847014530&partnerID=8YFLogxK

U2 - 10.2217/14622416.8.2.129

DO - 10.2217/14622416.8.2.129

M3 - Article

C2 - 17286534

AN - SCOPUS:33847014530

VL - 8

SP - 129

EP - 132

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 2

ER -